Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Samuel, Dr. Temesgen
Document related concepts
no text concepts found
Transcript
Temesgen Samuel, DVM, PhD Laboratory for Molecular Research on Bioactive Compounds Department of Pathobiology College of VM, Nursing & Allied Health Patterson Hall Room A408, Tuskegee, AL 36088 Phone 334-724-4547 (Office) -4671 (Lab) Fax 334-724-4110 [email protected] Education Graduation Year 1990 1998 Degree DVM PhD 1999 2002 Staff-Scientist Post- doctoral School Addis Ababa University, Ethiopia Hannover School of Veterinary Medicine, Germany Erlangen-Nuremberg University, Germany Burnham Institute for Medical Research, USA Major/Specialty Area Veterinary Medicine Cell Mol Biol Cell Mol Biol, cancer Cell Mol Biol, cancer research Teaching Molecular Biology, Microbiology Research Interest(s) 1. Molecular Determinants for the Bioactivity of Dietary Compounds: we are examining the molecular mechanisms through which dietary compounds, specifically flavonoids, exert their effect to prevent colon cancer. Signaling pathways that regulate the cell cycle, apoptosis, and NF-kB activation are the primary targets of interest. Sensitization to anticancer drugs through modulation of these pathways and drug-diet interaction are our specific focus areas. 2. Significance of biomarkers differentially expressed in aggressive colon cancers. In collaboration with the UAB, we are investigating the functional relevance of biomarkers highly expressed in microsatellite stable aggressive colon cancers. 3. Discovery and application of anti-cancer and anti-microbial bioactive compounds: In collaboration with TU and external investigators, we examine the potential bioactivity of natural compounds of diverse origin using cancer cells and common bacterial pathogens as targets. Recent Publications Samuel, T., Fadlalla, K., Mosely, L., Katkoori, V., Turner, T. and Manne, U. Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells (Accepted). Rodriguez, S., Fadlalla, K, Graham, T., Tameru, B., Fermin, C.D. and Samuel, T. Immunohistochemical Evaluation of AKT Protein Activation in Canine Mast Cell Tumors (Accepted). Fadlalla, K., Watson, A., Yehualaeshet, T. E., Turner, T., Samuel, T. Ruta graveolens extract induces DNA damage pathways and blocks Akt activation to inhibit cancer cell proliferation and survival. Anticancer Res, 31: (1) 233-241, 2011. PMCID: PMC3124362. Samuel, T., Fadlalla, K., Turner, T., Yehualaeshet, T. E. The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle. Nutrition & Cancer 62, 1025-1035, 2010. PMCID: PMC3021775. Garrison, J B, Samuel, T, Reed, J C.TRAF2-binding BIR1 domain of c-IAP2//MALT1 fusion protein is essential for activation of NF-[kappa]B. Oncogene 28, 1584–1593, 2009. Santoro, M. M., Samuel, T., Mitchell, T., Reed, J. C., and Stainier, D. Y. Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet, 39: 1397-1402, 2007. Hyer, M., Samuel, T, and Reed, JC. The FLIP-Side of Fas Signaling. Clinical Cancer Research, 12: 5929-5931, 2006. (Review) Samuel, T., Welsh, K, Lober, T., Togo, SH., Zapata, JM, and Reed, JC Distinct BIR Domains of cIAP1 Mediate Binding to and Ubiquitination of Tumor Necrosis Factor Receptor-associated Factor 2 and Second Mitochondrial Activator of Caspases. J Biol Chem, 281: 1080-1090, 2006. Service Activities Diagnostic Lab support, Departmental and University Committees for Research-related activities.
